Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
XFOR: Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029
3+ day, 6+ hour ago (75+ words) TradingView Mavorixafor's phase III trial for chronic neutropenia is on track with a reduced enrollment target and strong FDA alignment. Operational changes have improved enrollment, and a new study will address G-CSF reduction. Commercial launch is targeted for late 2028 or…...
LSHTM Secures Funding to Train Future Research Leaders
4+ day, 7+ hour ago (452+ words) Three funding awards will support programmes to help healthcare professionals develop their research careers The London School of Hygiene & Tropical Medicine (LSHTM) has received three major funding awards for programmes that will enable clinicians (including doctors, nurses, and allied health…...
An AI-generated lung medicine may also 'cure' ageing, trial shows
6+ day, 4+ hour ago (424+ words) The company says that data from the same trial shows a more intriguing possibility: that the drug could also slow the ageing process....
Tumor DNA ‘valuable’ for metastatic prostate cancer prognosis
1+ week, 4+ day ago (624+ words) Tumor DNA profiling could be used to identify which men with metastatic prostate cancer need aggressive treatment and those who may benefit from de-escalation.A model, trained and tested on nearly 2,500 veterans with metastatic hormone-sensitive prostate cancer, found those with…...
Ionetix Begins Shipping Astatine-211 to Support Preclinical and Clinical Trials
1+ week, 4+ day ago (930+ words) BioSpace Ionetix Begins Shipping Astatine-211 to Support Preclinical and Clinical Trials – New North American supply addresses a key barrier to advancing targeted alpha therapy – LANSING, Mich.--(BUSINESS WIRE)--Ionetix Corporation (“Ionetix” or the “Company”), a manufacturer of proprietary superconducting cyclotrons…...
CUT graduates scoop US$3,500 Cimas Healthathon 3.0 top prize
2+ week, 1+ day ago (16+ words) newsday.co.zw Discover more from newsday...
UT MD Anderson honors visionary leadership of Dr. Peter Pisters following retirement announcement; shares transition plans
2+ week, 4+ day ago (270+ words) If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start. Learn about clinical trials at UT…...
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
2+ week, 4+ day ago (200+ words) Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure DARE to PLAY Sildenafil Cream prescription dispensing and initial product revenue expected to commence in Q3 2026 The peer-reviewed article,…...
Mount Sinai’s $1m XPRIZE bet: reset immune system, slow aging
2+ week, 5+ day ago (549+ words) Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it and what stands between them and the competition’s…...
First Patient Dosed in Molecular Glue Degrader Trial for mCRPC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2+ week, 4+ day ago (498+ words) The MODeFIRe-1 of MRT-2359 plus apalutamide will focus on AR mutations in metastatic castration-resistant prostate cancer. The first patient has been dosed in MODeFIRe-1 (NCT07745361), a phase 2 study evaluating MRT-2359 in combination with apalutamide (Erleada) in patients with androgen receptor (AR)…...